Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.28 USD | +0.04% | +1.80% | -34.99% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.99% | 911M | |
+31.16% | 49.46B | |
+1.13% | 42.58B | |
+49.05% | 42.49B | |
-5.26% | 29.09B | |
+12.57% | 26.61B | |
-23.80% | 18.64B | |
+7.25% | 13.16B | |
+31.42% | 12.55B | |
+23.06% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Transcript : Viridian Therapeutics, Inc., Q4 2020 Earnings Call, Mar 25, 2021